The experimental HIV drug “Leronlimab” which was used to treat COVID-19 patients successfully entered its second stage of testing with the FDA and could be approved for use within 4 weeks.
According to a New York Post report, Leronlimab, made by CytoDyn Biotechnology Company, has been used to treat a number of severely ill patients in New York City hospitals, and the drug has helped a couple remove them from the ventilator.
AIDS drug–
–
“I think the FDA will be ready to work with us, I hope the approval will be accelerated,” CytoDyn CEO said in his comments to the newspaper.
He added, “A study in China indicated that the death rate among COVID-19 patients who need mechanical ventilation devices is more than 85%, so the world is in urgent need of treatment that can help these patients.”
AIDS drug–
–
Initial studies indicate that leronlimab can reduce the excessive immune response, known as cytokine, which can be caused by coronavirus infection, and cytokine storms can lead to pneumonia and even death.
– .
